James River Group Holdings, Ltd. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Amounts below are in U.S. dollars; financial results include continuing operations unless noted. JRG Re is presented as discontinued operations.
Business context
The Bermuda-based holding company operates specialty insurance businesses in Excess and Surplus Lines and Specialty Admitted Insurance, alongside Corporate and Other. The sale of casualty reinsurer JRG Re closed on April 16, 2024, after the quarter. The company also said its board had begun exploring strategic alternatives.
Financial results and key metrics
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Gross written premiums | $330.8 million | $353.5 million |
| Net written premiums | $138.2 million | $174.2 million |
| Net earned premiums | $171.7 million | $171.8 million |
| Total revenue | $201.1 million | $191.7 million |
| Income from continuing operations | $23.5 million | $7.9 million |
| Net income available to common shareholders | $12.8 million | $7.0 million |
| Adjusted net operating income (non-GAAP) | $14.8 million | $15.0 million |
| Operating cash flow, excluding restricted cash activity | $23.1 million | $18.4 million |
| Combined ratio | 95.3% | 94.0% |
- Continuing-operations pretax income was $33.0 million, versus $11.0 million; net income was $15.4 million, versus $9.6 million. Discontinued operations recorded an $8.1 million loss, compared with $1.7 million income. Diluted EPS was $0.35, versus $0.18.
- Underwriting profit was $8.1 million, down 20.5%. The loss ratio was 66.4% versus 66.7%; the expense ratio increased to 28.9% from 27.3%. The company reported a 12.2% adjusted net operating return on tangible equity, compared with 9.4%.
- Net investment income rose 22.8% to $22.6 million. Investment gains were $4.6 million, including $4.2 million of positive equity-security fair-value changes. Other comprehensive income reflected a $7.8 million loss, principally from unrealized investment losses.
- At March 31, total assets were $5.25 billion, including $1.71 billion of invested assets and $305.5 million of cash and cash equivalents. Shareholders’ equity was $539.5 million; Series A preferred shares of $144.9 million are classified as mezzanine equity.
- Balance-sheet senior debt was $222.3 million and junior subordinated debt was $104.1 million. The reported leverage ratio was 25.6%, below the 35% covenant maximum. The company had $185.8 million drawn on the unsecured 2013 revolving facility and $21.5 million of unsecured loans under the 2017 facility at quarter-end.
Changes and management commentary
- Gross written premiums fell 6.4%, while net written premiums fell 20.7%; net retention declined to 41.8% from 49.3%, reflecting increased cessions under a renewed quota-share treaty and a greater mix of fronting business. Net earned premiums were nearly unchanged.
- Excess and Surplus Lines underwriting profit declined to $18.5 million from $20.0 million, with an 87.3% combined ratio versus 86.8%. Specialty Admitted Insurance moved to $0.8 million underwriting profit from a $0.5 million loss; its combined ratio improved to 97.0% from 102.3%.
- Management attributed higher investment income to improved yields and higher invested assets. Higher compensation and professional-service costs contributed to the increase in the expense ratio; variable-rate debt costs also rose, with the average interest rate increasing to 8.0% from 6.9%.
- The JRG Re sale produced approximately $291.4 million of aggregate consideration: $152.4 million in cash and a $139 million distribution to the company. The estimated sales proceeds remain subject to post-closing adjustments; a further $2.5 million may be payable if specified conditions are met.
Outlook, risks and unusual items
- The filing provides no specific earnings or premium guidance. Management cautions that interim results are not necessarily indicative of full-year results and expects the JRG Re sale to support U.S. continuing-operations growth and improve future operating cash flows.
- JRG Re’s sale follows litigation over the buyer’s failure to close on the originally scheduled date. The sale closed April 16, but related litigation and the purchase-price adjustment process remained matters to monitor.
- Reserve adequacy is a key uncertainty: gross loss reserves were $2.66 billion, of which 67.9% was incurred but not reported. Management reported slight favorable prior-year development in continuing operations, excluding the legacy Rasier business and retroactive-reinsurance accounting.
- The company identifies credit exposure to Rasier and Aleka on the legacy commercial-auto arrangements if losses outpace collateral or estimates prove inadequate. At March 31, collateral securing their obligations totaled $154.5 million and $70.0 million, respectively; related Commercial Auto LPT recoverables were $67.4 million.
- The company’s U.S. insurance subsidiaries retained an A.M. Best A- rating with a negative outlook. JRG Re’s downgrade had triggered rating-covenant defaults under credit facilities; lenders waived the defaults through March 1, 2025, and the defaults were cured when JRG Re was sold. The 2013 facility’s secured commitment was reduced to $45 million after closing; the 2017 facility was amended, including higher applicable interest rates.
- A shareholder class-action settlement for $30 million had preliminary court approval; the company said insurers would fund the settlement and its $1.0 million deductible had been paid. A separate securities class action concerning reinstatement-premium recognition was being defended. Management reported disclosure controls effective at March 31 and no material change in internal control over financial reporting during the quarter.
- Other material risks include reserve-estimation uncertainty, reinsurance counterparty and market risks, inflation, catastrophe losses, rating changes, and the outcome of the strategic-alternatives process.
Investor verification priorities
- Check final JRG Re sale proceeds after post-closing adjustments, the status of related litigation, and whether the contingent $2.5 million payment condition is met.
- Track loss-reserve development, especially legacy Rasier claims, collateral adequacy, and recoveries under the loss portfolio transfers.
- Review premium retention, quota-share cessions, segment combined ratios, and the continued performance of major fronting relationships.
- Monitor debt-facility amendments, borrowing costs, covenant compliance, and the A.M. Best outlook for the U.S. insurance subsidiaries.
- Assess whether investment-income growth is sustained and how interest-rate, credit, and equity-market movements affect investment values and earnings.
- Follow the strategic-alternatives review, the shareholder litigation, and the effect of preferred dividends and potential conversion dilution.